Investing

Merck: Gardasil 9 Long-Term Followup Study Finds No Serious Adverse Effects or Deaths

By Mary de Wet

Merck said a 10-year followup study of girls and boys who received a three-dose regimen of Gardasil 9 found no serous adverse effects or deaths.

Gardasil 9 is a human papillomavirus 9-valent vaccine given to children ages 9 to 15 years. It targets HPV types that cause about 80% of cervical cancers. HPV is also responsible for causing genital warts and certain types of vulvar, vaginal and anal cancers.

The study showed sustained HPV-antibody responses at 10 years after the third dose in boys and girls, Merck said.

Among girls, there were no cases of vaccine-targeted HPV type high-grade disease, certain cancers or external genital warts observed, the company said.

In boys, there were no cases of vaccine-targeted HPV type disease, certain studied cancers or external genital warts observed, Merck said.

The study was conducted at 40 sites in 13 countries and involved 1,272 participants, the company said.


Write to Mary de Wet at mary.dewet@dowjones.com


Read the full article here

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News

nLIGHT, Inc. (NASDAQ:LASR) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants John Marchetti – VP of Corporate Development and...

News

This article was written by Follow I am a value investor focused on opportunities in undervalued micro-cap and small-cap stocks, with a particular focus...

News

This article was written by Follow About My Writing: I am currently focused on income investing through either common shares, preferred shares, or bonds. ...

News

908 Devices Inc. (NASDAQ:MASS) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Kelly Gura – Gilmartin GroupKevin Knopp –...

Copyright © 2023 Repay Down. All Rights Reserved.

Exit mobile version